In people with bone cancer, levels of calcium in the blood rise as the cancer breaks down the bone. The cancer cells over-produce Parathyroid Related Peptide as they break down the bone. PTH-related peptide (PTHrP) is the principle mediator of humoral hypercalcemia of malignancy. PTHrP production results in hypercalcemia and hypophosphatemia. PTH-rP has been found to be elevated in 50% to 90% of patients with hypercalcemia of malignancy.
Price: $229.00 |
